-transparent.png){kind=logo}
In a prospective trial of aerosolized pentamidine as secondary prophylaxis for Pneumocystis carinii pneumonia (PCP) 18 patients received 400 mg once weekly for a mean period of 15.5 months. Pentamidine aerosol was administered with an MA2 jet nebulizer. No PCP relapses were observed and no serious side effects occurred.
Related Publications
L Flamholc, and
S Haidl, and
E Westin, and
L Borgdalen, and
T Prellner
February 1991,
Southern medical journal,
L Flamholc, and
S Haidl, and
E Westin, and
L Borgdalen, and
T Prellner
June 1991,
Annals of internal medicine,
L Flamholc, and
S Haidl, and
E Westin, and
L Borgdalen, and
T Prellner
November 1988,
Drug intelligence & clinical pharmacy,
L Flamholc, and
S Haidl, and
E Westin, and
L Borgdalen, and
T Prellner
May 1993,
Bone marrow transplantation,
L Flamholc, and
S Haidl, and
E Westin, and
L Borgdalen, and
T Prellner
May 2001,
Chest,
L Flamholc, and
S Haidl, and
E Westin, and
L Borgdalen, and
T Prellner
January 1993,
Infection,
L Flamholc, and
S Haidl, and
E Westin, and
L Borgdalen, and
T Prellner
October 1990,
The Journal of infectious diseases,
L Flamholc, and
S Haidl, and
E Westin, and
L Borgdalen, and
T Prellner
January 1990,
Journal of the Royal Society of Medicine,
L Flamholc, and
S Haidl, and
E Westin, and
L Borgdalen, and
T Prellner
July 1987,
Antimicrobial agents and chemotherapy,
L Flamholc, and
S Haidl, and
E Westin, and
L Borgdalen, and
T Prellner
November 1991,
Chest,
